CGTX (Cognition Therapeutics, Inc. Common Stock) Stock Analysis - Analyst Ratings

Cognition Therapeutics, Inc. Common Stock (CGTX) is a publicly traded Healthcare sector company. As of May 21, 2026, CGTX trades at $1.24 with a market cap of $97.55M and a P/E ratio of -3.98. CGTX moved +15.32% today. Year to date, CGTX is -7.86%; over the trailing twelve months it is +281.43%. Its 52-week range spans $0.22 to $3.83. Analyst consensus is buy with an average price target of $3.50. Rallies surfaces CGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate CGTX?

2 analysts cover CGTX: 0 strong buy, 2 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $3.50.

CGTX Key Metrics

Key financial metrics for CGTX
MetricValue
Price$1.24
Market Cap$97.55M
P/E Ratio-3.98
EPS$-0.32
Dividend Yield0.00%
52-Week High$3.83
52-Week Low$0.22
Volume19.80K
Avg Volume0
Revenue (TTM)$0
Net Income$-23.49M
Gross Margin0.00%

CGTX Analyst Consensus

2 analysts cover CGTX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.50.

Latest CGTX News

Recent CGTX Insider Trades

  • Doyle John Brendan bought 10.00K (~$11.30K) on Apr 16, 2026.
  • Ricciardi Lisa bought 9.18K (~$10.09K) on Apr 16, 2026.
  • Caggiano Anthony bought 10.00K (~$11.10K) on Apr 16, 2026.

Common questions about CGTX

What do analysts rate CGTX?
2 analysts cover CGTX: 0 strong buy, 2 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $3.50.
Does Rallies show CGTX price targets?
Yes. Rallies tracks CGTX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is CGTX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CGTX. It does not provide personalized investment advice.
CGTX

CGTX